First quarter earnings are in full swing. Here is a look at what some companies are saying to analysts during their quarterly calls. Celgene talks up Revlimid; Alkermes bullish on Aristada launch; Victoza market share threatened by Trulicity; Acorda plans for Phase III in post-stroke; Soliris still backbone at Alexion.

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.

The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.